ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 281 filers reported holding ROYALTY PHARMA PLC in Q2 2022. The put-call ratio across all filers is 0.10 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $40,581,738 | -14.6% | 1,495,274 | -3.3% | 0.00% | -20.0% |
| Q2 2023 | $47,540,371 | -29.9% | 1,546,531 | -17.8% | 0.01% | -28.6% |
| Q1 2023 | $67,823,227 | +29.7% | 1,882,410 | +42.2% | 0.01% | +16.7% |
| Q4 2022 | $52,305,756 | -13.2% | 1,323,526 | -11.7% | 0.01% | -14.3% |
| Q3 2022 | $60,252,000 | -12.6% | 1,499,546 | -8.5% | 0.01% | -12.5% |
| Q2 2022 | $68,902,000 | -9.8% | 1,638,927 | -16.4% | 0.01% | +14.3% |
| Q1 2022 | $76,382,000 | -6.5% | 1,960,528 | -4.4% | 0.01% | -12.5% |
| Q4 2021 | $81,721,000 | +15.7% | 2,050,689 | +4.9% | 0.01% | +14.3% |
| Q3 2021 | $70,646,000 | +8.2% | 1,954,751 | +22.7% | 0.01% | 0.0% |
| Q2 2021 | $65,278,000 | +5.0% | 1,592,556 | +11.7% | 0.01% | 0.0% |
| Q1 2021 | $62,197,000 | +181.0% | 1,425,879 | +222.3% | 0.01% | +133.3% |
| Q4 2020 | $22,138,000 | +231.0% | 442,339 | +178.2% | 0.00% | +200.0% |
| Q3 2020 | $6,689,000 | +4450.3% | 158,998 | +5145.7% | 0.00% | – |
| Q2 2020 | $147,000 | – | 3,031 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $294,957,000 | 88.74% |
| Vantage Consulting Group Inc | 8,705,551 | $379,735,000 | 76.23% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $116,930,000 | 72.07% |
| HARVARD MANAGEMENT CO INC | 10,714,284 | $467,357,000 | 26.11% |
| ROBERT WOOD JOHNSON FOUNDATION | 970,151 | $4,231,798,000 | 21.59% |
| Brown University | 381,759 | $16,652,000 | 11.44% |
| Overbrook Management Corp | 771,155 | $33,638,000 | 7.48% |
| SpiderRock Advisors, LLC | 778,800 | $34,236,000 | 4.79% |
| Renaissance Capital LLC | 452,948 | $19,758,000 | 2.93% |
| Lagoda Investment Management, L.P. | 104,835 | $4,573,000 | 2.28% |